Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bi
Non vérifié

Biogen Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceManagement/Organisation d'EntrepriseMédecine Santé Bien-être

68 communiqués de presse

Voir tous les communiqués de presse
17/06/2026
Biotechnologie
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
04/06/2026
Biotechnologie
Annonces Économiques
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
03/06/2026
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
14/05/2026
Biotechnologie
Médecine Santé Bien-être
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotechnologie
Management/Organisation d'Entreprise
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
31/03/2026
Biotechnologie
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
30/03/2026
Biotechnologie
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotechnologie
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
19/03/2026
Biotechnologie
Médecine Santé Bien-être
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
11/03/2026
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
Source
Biogen Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0